Survey
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Ticker(s): LLY, NVO, AZN, VKTXSurvey Results include 20 physicians.
How many patients with Type 2 Diabetes do you have under your care?
Are you currently prescribing or managing GLP-1 treatments for patients with Diabetes?
How many of your patients are eligible for a GLP-1 treatment?
How
many of your patients are currently on a GLP-1 treatment?
- Mounjaro (tirzepatide):
- Ozempic (semaglutide):
- Rybelsus (semaglutide):
- Victoza, Saxenda (Liraglutide):
- Trulicity (dulaglutide):
- Bydureon BCise (exenatide extended-release):
- Byetta (exenatide)
- Other:
Which of the following GLP-1 treatments has the most promise?
Why is that? Please answer in response to your answer above.
How many patients have started Ozempic (semaglutide) in the past 30 days?
How many patients have discontinued Ozempic (semaglutide) in the past 30 days?
How many patients do you expect to use Ozempic
(semaglutide) at the following time points (cumulative)?
- 90 days
- 1 year
- 3 years
How many patients have started Mounjaro (tirzepatide) in the past 30 days?
How many patients have discontinued Mounjaro (tirzepatide) in the past 30 days?
How many patients do you expect to use Mounjaro
(tirzepatide) at the following time points (cumulative)?
- 90 days
- 1 year
- 3 years
Please elaborate on your view of Mounjaro (tirzepatide). Please be specific.
How would you rate Mounjaro (tirzepatide) on the
following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
Do the side effects of Mounjaro (tirzepatide) limit your prescribing rate?
Which
side effects limit your prescribing of Mounjaro (tirzepatide)?
What changes, if any, have you noticed with payor reimbursement and insurance for diabetes and weight loss treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
